Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Interleukin-17 limits hypoxia-inducible factor 1α and development of hypoxic granulomas during tuberculosis
Racquel Domingo-Gonzalez, … , Joaquín Zúñiga, Shabaana A. Khader
Racquel Domingo-Gonzalez, … , Joaquín Zúñiga, Shabaana A. Khader
Published October 5, 2017
Citation Information: JCI Insight. 2017;2(19):e92973. https://doi.org/10.1172/jci.insight.92973.
View: Text | PDF
Research Article Infectious disease Inflammation

Interleukin-17 limits hypoxia-inducible factor 1α and development of hypoxic granulomas during tuberculosis

  • Text
  • PDF
Abstract

Mycobacterium tuberculosis (Mtb) is a global health threat, compounded by the emergence of drug-resistant strains. A hallmark of pulmonary tuberculosis (TB) is the formation of hypoxic necrotic granulomas, which upon disintegration, release infectious Mtb. Furthermore, hypoxic necrotic granulomas are associated with increased disease severity and provide a niche for drug-resistant Mtb. However, the host immune responses that promote the development of hypoxic TB granulomas are not well described. Using a necrotic Mtb mouse model, we show that loss of Mtb virulence factors, such as phenolic glycolipids, decreases the production of the proinflammatory cytokine IL-17 (also referred to as IL-17A). IL-17 production negatively regulates the development of hypoxic TB granulomas by limiting the expression of the transcription factor hypoxia-inducible factor 1α (HIF1α). In human TB patients, HIF1α mRNA expression is increased. Through genotyping and association analyses in human samples, we identified a link between the single nucleotide polymorphism rs2275913 in the IL-17 promoter (–197G/G), which is associated with decreased IL-17 production upon stimulation with Mtb cell wall. Together, our data highlight a potentially novel role for IL-17 in limiting the development of hypoxic necrotic granulomas and reducing disease severity in TB.

Authors

Racquel Domingo-Gonzalez, Shibali Das, Kristin L. Griffiths, Mushtaq Ahmed, Monika Bambouskova, Radha Gopal, Suhas Gondi, Marcela Muñoz-Torrico, Miguel A. Salazar-Lezama, Alfredo Cruz-Lagunas, Luis Jiménez-Álvarez, Gustavo Ramirez-Martinez, Ramón Espinosa-Soto, Tamanna Sultana, James Lyons-Weiler, Todd A. Reinhart, Jesus Arcos, Maria de la Luz Garcia-Hernandez, Michael A. Mastrangelo, Noor Al-Hammadi, Reid Townsend, Joan-Miquel Balada-Llasat, Jordi B. Torrelles, Gilla Kaplan, William Horne, Jay K. Kolls, Maxim N. Artyomov, Javier Rangel-Moreno, Joaquín Zúñiga, Shabaana A. Khader

×

Figure 6

HIF1α inhibition in vivo reverses IL-17 neutralization–mediated susceptibility to Mtb.

Options: View larger image (or click on image) Download as PowerPoint
HIF1α inhibition in vivo reverses IL-17 neutralization–mediated suscepti...
(A–D) Following infection with approximately 100 CFU Mycobacterium tuberculosis (Mtb) clinical strain HN878, FeJ mice received isotype or IL-17–neutralizing antibody via i.p. from 10 to 24 days postinfection (d.p.i.). At 24 d.p.i., anti–IL-17–treated mice received 2 mg/kg HIF1α inhibitor (acriflavine [acrifl]) or vehicle (veh) from 24 to 36 d.p.i. Mice were harvested at 37 d.p.i. and bacterial burden (n = 5 mice/isotype, n = 7 mice/anti–IL-17, n = 5 mice/anti–IL-17 + acrifl) (A), H&E–stained lungs (B), and inflammation (n = 5 mice/isotype, n = 6 mice/anti–IL-17, n = 7 mice/anti–IL-17 + acrifl) (C) were quantified. (D) HIF1α-expressing cells in representative granulomas in the lungs were measured by immunofluorescence microscopy (n = 5 mice/isotype, n = 8 mice/anti–IL-17, n = 7 mice/anti–IL-17 + acrifl). All data shown as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA (A, C, and D).

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts